Navigation Links
New Influenza Drug Inavir(R) TwinCaps(R) Launched in Japan
Date:10/21/2010

New Influenza Drug Inavir(R) TwinCaps(R) Launched in Japan -- LOURES, Portugal, October 21, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, New Products & Services Click to view news release full screen  

New Influenza Drug Inavir(R) TwinCaps(R) Launched in Japan

 

LOURES, Portugal, October 21, 2010 /PRNewswire/ -- Hovione has been advised by Daiichi Sankyo Company Ltd that Inavir(R) has been launched in Japan.

Inavir(R) is an inhalation powder which is delivered by the TwinCaps(R) inhaler to treat influenza. TwinCaps(R) was specifically designed by Hovione for this indication and is licensed to Daiichi Sankyo and to Biota Holdings Ltd.

Daiichi Sankyo has demonstrated that one 40mg dose of Inavir(R) active ingredient, laninamivir octanoate, is as effective as oseltamivir, a drug which needs to be taken over the course of 5 days. Daiichi Sankyo has announced it plans to supply the Japanese market with 4 million packs by end of March 2011, of which 2 million will be supplied by end of December 2010. The reimbursement price of the pack for adult treatment has been set at JPY 4161 (approx. EUR36; US$50).

TwinCaps(R) has been designed for extreme ease of use and very low cost. Daiichi Sankyo and Biota are responsible for licensing Ianinamivir.

About Hovione

Hovione is a leading developer of inhaled drug products, with experience in anti-virals and proteins delivered by inhalation, as well as inhaler development. It is an international company with 51 years' experience in Active Pharmaceutical Ingredient integrated development and compliant manufacture, from molecule to unit dose. In the inhalation area, Hovione is the only independent company offering such a broad range of services.

For more information about Hovione: please visit the Hovione site at http://www.hovione.com or contact Corporate Communications Isabel Pina +351-21-982-9362 e-mail: ipina@hovione.com
'/>"/>

SOURCE Hovione
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GenVec Receives Second-Year Funding From SAIC for HIV and Influenza Vaccine Development
2. Hoviones TwinCaps(R) Dry-powder Inhaler Approved in Japan as Part of Inavir(R) Influenza Treatment
3. FDA Accepts Sanofi Pasteur File Submission for Novel Influenza Vaccine Delivered by Intradermal Microinjection
4. Consumers Encouraged to Get Immunized Against Influenza
5. FDA Approves Vaccines for the 2010-2011 Influenza Season
6. NOVAVAX Announces Issuance of Key U.S. Patent for Influenza Virus-Like Particle (VLP) Vaccines
7. IDRI and PATH Enter into Research Collaboration Agreement to Evaluate Novel Adjuvants to Enhance Pandemic Influenza Vaccines
8. Novavaxs Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
9. Adamas Pharmaceuticals TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
10. AmpVacs a Broadly Protective Synthetic Influenza A Vaccine
11. NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... -- According to the new market ... by Components (Software, Service), Delivery Modes (Web-based, On-premises, ... Companies, Clinical Research Organization, Medical Device Companies) Global ... 2022", published by Scalar Market Research, the global ... to grow at a healthy CAGR of 14.30% ...
(Date:12/7/2016)... Dec. 7, 2016   TraceLink Inc ., ... connecting the Life Sciences supply chain and eliminating ... announced that Tjoapack has selected TraceLink,s serialization solutions ... comply with the rapidly approaching serialization deadlines for ... in 2017 and the EU Falsified Medicines Directive ...
(Date:12/7/2016)... Dec. 7, 2016  Varian Medical Systems (NYSE: ... previously announced plans to separate its Imaging Components business.  ... tax-free distribution to Varian stockholders of common stock in ... will hold the Imaging Components business.  As part of ... by the end of January 2017, Varian will receive ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Castle Dermatology Institute is ... ways to restore a more youthful appearance to the face. Dr. Peyman Ghasri and ... with a variety of other treatments, to rejuvenate and renew the facial appearance. ...
(Date:12/7/2016)... MA (PRWEB) , ... December 07, 2016 , ... They ... They are sisters and wives, brothers and fathers, from New England and around the ... and its stigma, and are brought together in a beautiful and compelling new photographic ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... consultation services from offices located in South Lyon, Dewitt, Williamston, East Lansing, Ann ... basketball coach who needs treatment for a brain tumor. , Jason Bauer and ...
(Date:12/7/2016)... ... ... One of two inventors from Glen Burnie, Md., has a granddaughter who uses ... why the co-inventor and I have designed a new and better way to secure ... the patent-pending AV-AIR, a device that serves as an alternative to conventional methods of ...
(Date:12/7/2016)... AUSTIN, TX (PRWEB) , ... OCTOBER XX, 2016 ... ... may help solve another mystery. A new study entitled “Canine Filamentous Dermatitis ... Morgellons disease can occur in dogs. The study was published in the prestigious ...
Breaking Medicine News(10 mins):